Interventions: CagriSema (Cagrilintide B and Semaglutide I), placebo Primary Outcome Measure: Relative change in body weight Time Frame: From baseline (week 0) to week 80 Study Details Source VK2735 for Weight Management Phase 3 (VANQUISH 1) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes
it is one of the small maintenance items that keep the engine running
Sharp, Protected Vision Starts with Lutein Rx-Eye!*
Understanding B-Vitamins in Goats Understanding the significance of water-soluble B vitamins, particularly Vitamin B1 (thiamine) and Vitamin B12, is pivotal
Over time, these factors can lower energy, slow metabolism, impact focus, and make it harder to feel your best